BlackRock, Inc. Reports Decreased Ownership in Avidity Biosciences, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A, reporting a significant decrease in its ownership of Avidity Biosciences, Inc. common stock. As of September 30, 2025, BlackRock, Inc. owns 8,631,771 shares, representing 6.4% of the total outstanding shares. This marks a decrease of 85.38% in both the number of shares and the value of the holdings compared to the previous filing. The filing indicates that BlackRock, Inc. has sole voting power over 8,455,367 shares and sole dispositive power over all 8,631,771 shares. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.